Agriculture and Biotechnology Industry Veteran to Help Guide
Company's Growth in Bioplastics and Chemicals
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix,
Inc. (NASDAQ: MBLX), a bioscience company focused on developing
clean, sustainable solutions for plastics, chemicals and energy, today
announced that Barbara H. Wells, Ph.D., has joined its board of
directors, effective June 6, 2011. Dr. Wells brings 26 years of
experience in the agriculture and biotechnology industries to help
Metabolix grow its renewable bioplastics and chemicals businesses.
Dr. Wells is currently the president and chief executive officer of ArborGen,
which she joined in 2002. Prior to ArborGen, she was the vice president
in charge of Latin American growth initiatives and investments for
Emergent Genetics, Inc., an agricultural investment firm. Dr. Wells also
spent 18 years at Monsanto where her roles included serving as
co-managing director of Monsanto Brazil and leader of the Roundup Ready
soybean team. Throughout her career, she has developed international
commercial and technical experience in agriculture, biotechnology and
forestry.
"We are very pleased that Barbara Wells will be joining our board. Her
broad experience and insight into biotechnology and agriculture will be
exceptionally valuable to Metabolix as the company grows its business in
these markets," said Rick Eno, president and CEO of Metabolix. "Barbara
also brings a unique international perspective to us through her years
of living and working in South America, which will help the company
shape our international strategy. We are looking forward to her
contributions."
Dr. Wells received her Ph.D. in agronomy from Oregon State University.
She earned her M.S. degree in plant pathology and B.S. degree with
honors in horticulture from the University of Arizona. She served as the
president of the board of directors of Produsem S.A. in Argentina, and
the boards of Monsanto Brazil, Monsoy and Maeda Delta Pine Monsanto JV.
She currently serves on the executive committee of the board of
directors of the Biotechnology Industry Organization and is vice
chairman of the Food and Agricultural Sector board. She is an advisory
committee member of the Joint BioEnergy Institute and has previously
served as a board member for the Forest Biotechnology Institute.
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world's needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is now
developing and commercializing Mirel™, a family of high-performance
bioplastics, which are biobased and biodegradable alternatives to many
petroleum-based plastics, through Telles, a joint venture between
Metabolix and Archer Daniels Midland Company. Metabolix is also
developing biosourced industrial chemicals and a proprietary platform
technology for co-producing plastics, chemicals and energy, from crops
such as switchgrass, oilseeds and sugarcane. For more information,
please visit http://www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding
expectations for Metabolix research and development programs, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission.
Metabolix assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
Media:
Schwartz Communications
Keith Giannini or Jen Barlow,
781-684-0770
metabolix@schwartzcomm.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix, Inc.
News Provided by Acquire Media
